Details of the Drug Combinations

General Information of This Drug (ID: DMT5GNL)

Drug Name

Romidepsin DMT5GNL

Synonyms

Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous T-cell lymphoma	2B01	Approved	[1]
Gastrin-producing neuroendocrine tumor	N.A.	Approved	[2]
Glucagonoma	N.A.	Approved	[2]
Insulinoma	2C10.1	Approved	[2]
Lung carcinoid tumor	N.A.	Approved	[2]
Melanoma	2C30	Approved	[2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified	N.A.	Approved	[2]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[2]
Urethral cancer	2C93	Approved	[2]
Peripheral T-cell lymphoma	2A90.C	Phase 3	[3]
Renal cell carcinoma	2C90	Phase 3	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

432 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABIRATERONE + Romidepsin	DCR5DNE	ABIRATERONE	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
ABIRATERONE + Romidepsin	DC5HPJ3	ABIRATERONE	Malignant melanoma (Cell Line: LOX IMVI)	[4]
ABT-263 + Romidepsin	DCSDWLL	ABT-263	Ewing sarcoma (Cell Line: TC-71)	[4]
Amonafide + Romidepsin	DCTJB04	Amonafide	Adenocarcinoma (Cell Line: A549)	[5]
Amonafide + Romidepsin	DCCJ682	Amonafide	Adenocarcinoma (Cell Line: HT29)	[5]
Amonafide + Romidepsin	DCE3S4H	Amonafide	Adenocarcinoma (Cell Line: HCT-15)	[5]
Amonafide + Romidepsin	DCZSAB5	Amonafide	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Amonafide + Romidepsin	DC76QKE	Amonafide	Astrocytoma (Cell Line: U251)	[5]
Amonafide + Romidepsin	DCBEA7M	Amonafide	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Amonafide + Romidepsin	DCTE0YA	Amonafide	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Amonafide + Romidepsin	DC8RW78	Amonafide	Malignant melanoma (Cell Line: UACC62)	[5]
Amonafide + Romidepsin	DCSZNVQ	Amonafide	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Amonafide + Romidepsin	DCVLFRL	Amonafide	Melanoma (Cell Line: MALME-3M)	[5]
Amonafide + Romidepsin	DCELCJ2	Amonafide	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Amonafide + Romidepsin	DCFVNMP	Amonafide	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[5]
Amonafide + Romidepsin	DCMY1LU	Amonafide	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Amonafide + Romidepsin	DCHUBHY	Amonafide	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Amonafide + Romidepsin	DC9S0JK	Amonafide	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Anastrozole + Romidepsin	DCUV14I	Anastrozole	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Anastrozole + Romidepsin	DCPKFO1	Anastrozole	Clear cell renal cell carcinoma (Cell Line: TK-10)	[5]
Anastrozole + Romidepsin	DCX20P7	Anastrozole	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Anastrozole + Romidepsin	DC3KSM8	Anastrozole	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Anastrozole + Romidepsin	DCK1WCH	Anastrozole	Glioma (Cell Line: SF-295)	[5]
Anastrozole + Romidepsin	DCUCTAF	Anastrozole	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[5]
Anastrozole + Romidepsin	DC4RM5R	Anastrozole	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Anastrozole + Romidepsin	DCY7FBF	Anastrozole	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Anastrozole + Romidepsin	DCHS7ZE	Anastrozole	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Anastrozole + Romidepsin	DCOD6KC	Anastrozole	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Anastrozole + Romidepsin	DC6OPB7	Anastrozole	Melanoma (Cell Line: UACC-257)	[5]
Anastrozole + Romidepsin	DCDMINM	Anastrozole	Melanoma (Cell Line: MALME-3M)	[5]
Anastrozole + Romidepsin	DC9IGYM	Anastrozole	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Anastrozole + Romidepsin	DCE5YJ2	Anastrozole	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Anastrozole + Romidepsin	DCWLL2V	Anastrozole	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[5]
Anastrozole + Romidepsin	DCV34F4	Anastrozole	Prostate carcinoma (Cell Line: PC-3)	[5]
Anastrozole + Romidepsin	DCHNQ51	Anastrozole	Renal cell carcinoma (Cell Line: UO-31)	[5]
Anastrozole + Romidepsin	DCS672W	Anastrozole	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Arfolitixorin + Romidepsin	DC3680L	Arfolitixorin	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Arfolitixorin + Romidepsin	DC7AXSR	Arfolitixorin	Adenocarcinoma (Cell Line: A549)	[4]
Arfolitixorin + Romidepsin	DCFT49Y	Arfolitixorin	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Arfolitixorin + Romidepsin	DC4Q928	Arfolitixorin	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Arfolitixorin + Romidepsin	DC62PTK	Arfolitixorin	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
Arfolitixorin + Romidepsin	DCBYT0Q	Arfolitixorin	Malignant melanoma (Cell Line: LOX IMVI)	[4]
Arfolitixorin + Romidepsin	DC8WV6U	Arfolitixorin	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[4]
Arfolitixorin + Romidepsin	DCMOULR	Arfolitixorin	Prostate carcinoma (Cell Line: PC-3)	[4]
Artemether + Romidepsin	DC1RAB1	Artemether	Ewing sarcoma (Cell Line: TC-71)	[5]
AZD8055 + Romidepsin	DCJSR1I	AZD8055	Ewing sarcoma (Cell Line: TC-71)	[5]
Bardoxolone methyl + Romidepsin	DCOC2X4	Bardoxolone methyl	Ewing sarcoma (Cell Line: TC-71)	[5]
BIO-300 + Romidepsin	DCVMLZ9	BIO-300	Astrocytoma (Cell Line: SNB-19)	[5]
BIO-300 + Romidepsin	DC49RSL	BIO-300	Glioblastoma (Cell Line: SNB-75)	[5]
BIO-300 + Romidepsin	DC1CWBL	BIO-300	Renal cell carcinoma (Cell Line: SN12C)	[5]
BIO-300 + Romidepsin	DCP5DUS	BIO-300	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
BIO-300 + Romidepsin	DCFK8FY	BIO-300	Carcinoma (Cell Line: RXF 393)	[6]
BIO-300 + Romidepsin	DCMTA8T	BIO-300	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
BIO-300 + Romidepsin	DCFJ0X6	BIO-300	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
BIO-300 + Romidepsin	DCJ5PU4	BIO-300	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
BIO-300 + Romidepsin	DCZ2CU0	BIO-300	Adenocarcinoma (Cell Line: OVCAR3)	[4]
BIO-300 + Romidepsin	DCXULNA	BIO-300	Adenocarcinoma (Cell Line: A549)	[4]
BIO-300 + Romidepsin	DCHHI9X	BIO-300	Adenocarcinoma (Cell Line: HCC-2998)	[4]
BIO-300 + Romidepsin	DCCKDZN	BIO-300	Adenocarcinoma (Cell Line: HCT-15)	[4]
BIO-300 + Romidepsin	DCTAMYK	BIO-300	Adenocarcinoma (Cell Line: HT29)	[4]
BIO-300 + Romidepsin	DCTILGH	BIO-300	Adenocarcinoma (Cell Line: SW-620)	[4]
BIO-300 + Romidepsin	DCAIDTE	BIO-300	Amelanotic melanoma (Cell Line: MDA-MB-435)	[4]
BIO-300 + Romidepsin	DCBCP7G	BIO-300	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[4]
BIO-300 + Romidepsin	DCIQFVP	BIO-300	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
BIO-300 + Romidepsin	DCHOUL0	BIO-300	Lung adenocarcinoma (Cell Line: HOP-62)	[4]
BIO-300 + Romidepsin	DCR6JDE	BIO-300	Lung adenocarcinoma (Cell Line: EKVX)	[4]
BIO-300 + Romidepsin	DCLX41I	BIO-300	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
BIO-300 + Romidepsin	DCYRSEC	BIO-300	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
BIO-300 + Romidepsin	DC3SKS0	BIO-300	Malignant melanoma (Cell Line: UACC62)	[4]
BIO-300 + Romidepsin	DCWOBRV	BIO-300	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[4]
BIO-300 + Romidepsin	DCSZ5OY	BIO-300	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
BIO-300 + Romidepsin	DC09J6O	BIO-300	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
BIO-300 + Romidepsin	DC5Z8OO	BIO-300	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[4]
Bleomycin + Romidepsin	DCYRNCL	Bleomycin	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Bleomycin + Romidepsin	DC9NDWA	Bleomycin	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Bleomycin + Romidepsin	DC1ZD9I	Bleomycin	Adenocarcinoma (Cell Line: A549)	[4]
Bleomycin + Romidepsin	DCE1A9H	Bleomycin	Adenocarcinoma (Cell Line: HCT-15)	[4]
Bleomycin + Romidepsin	DCPRQV3	Bleomycin	Amelanotic melanoma (Cell Line: MDA-MB-435)	[4]
Bleomycin + Romidepsin	DCPTSRN	Bleomycin	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Bleomycin + Romidepsin	DCGZX52	Bleomycin	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Bleomycin + Romidepsin	DCIHGP8	Bleomycin	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
Bleomycin + Romidepsin	DCPT2H8	Bleomycin	Malignant melanoma (Cell Line: LOX IMVI)	[4]
Bleomycin + Romidepsin	DC92NRY	Bleomycin	Melanoma (Cell Line: MALME-3M)	[4]
Bleomycin + Romidepsin	DCJR6ZB	Bleomycin	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
Bleomycin + Romidepsin	DCP69O5	Bleomycin	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[4]
Cabazitaxel + Romidepsin	DC5BINF	Cabazitaxel	Adenocarcinoma (Cell Line: HCT-15)	[5]
Cabazitaxel + Romidepsin	DC8SDAG	Cabazitaxel	Adenocarcinoma (Cell Line: SW-620)	[5]
Cabazitaxel + Romidepsin	DC1ZBIS	Cabazitaxel	Chronic myelogenous leukemia (Cell Line: K-562)	[5]
Cabazitaxel + Romidepsin	DCU1T2L	Cabazitaxel	Glioma (Cell Line: SF-268)	[5]
Cabazitaxel + Romidepsin	DC6DW7I	Cabazitaxel	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Cabazitaxel + Romidepsin	DCUMGKX	Cabazitaxel	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Cabazitaxel + Romidepsin	DC7NK7R	Cabazitaxel	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Cabazitaxel + Romidepsin	DCQDAMB	Cabazitaxel	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[5]
Cabazitaxel + Romidepsin	DC0IYBW	Cabazitaxel	Renal cell carcinoma (Cell Line: UO-31)	[5]
Carfilzomib + Romidepsin	DCUDWUG	Carfilzomib	Ewing sarcoma (Cell Line: TC-71)	[5]
Crizotinib + Romidepsin	DCUD41N	Crizotinib	Chronic myelogenous leukemia (Cell Line: K-562)	[5]
Crizotinib + Romidepsin	DCG82BY	Crizotinib	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Crizotinib + Romidepsin	DCQN3JE	Crizotinib	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Crizotinib + Romidepsin	DCI75I1	Crizotinib	Renal cell carcinoma (Cell Line: UO-31)	[5]
Dacarbazine + Romidepsin	DCBHO58	Dacarbazine	Adenocarcinoma (Cell Line: A549)	[5]
Dacarbazine + Romidepsin	DCJ8DJO	Dacarbazine	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Dacarbazine + Romidepsin	DC1INYN	Dacarbazine	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Dacarbazine + Romidepsin	DCJI44M	Dacarbazine	Clear cell renal cell carcinoma (Cell Line: TK-10)	[5]
Dacarbazine + Romidepsin	DCHYN2U	Dacarbazine	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Dacarbazine + Romidepsin	DC9C9NT	Dacarbazine	Glioblastoma (Cell Line: SNB-75)	[5]
Dacarbazine + Romidepsin	DC7WSEP	Dacarbazine	Glioma (Cell Line: SF-268)	[5]
Dacarbazine + Romidepsin	DCC800G	Dacarbazine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Dacarbazine + Romidepsin	DC8FXOF	Dacarbazine	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Dacarbazine + Romidepsin	DC2SAYU	Dacarbazine	Melanoma (Cell Line: MALME-3M)	[5]
Dacarbazine + Romidepsin	DCX4ZA6	Dacarbazine	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Dexrazoxane + Romidepsin	DCZRTXP	Dexrazoxane	Adenocarcinoma (Cell Line: SW-620)	[5]
Dexrazoxane + Romidepsin	DCOIAZ6	Dexrazoxane	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Dexrazoxane + Romidepsin	DCYGFAR	Dexrazoxane	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Dexrazoxane + Romidepsin	DC3I8JM	Dexrazoxane	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Dexrazoxane + Romidepsin	DC8OJ6W	Dexrazoxane	Malignant melanoma (Cell Line: LOX IMVI)	[4]
Dexrazoxane + Romidepsin	DC8510S	Dexrazoxane	Melanoma (Cell Line: MALME-3M)	[4]
Digitoxin + Romidepsin	DCI9LTA	Digitoxin	Adenocarcinoma (Cell Line: NCIH23)	[5]
Digitoxin + Romidepsin	DCHMJNT	Digitoxin	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Docetaxel + Romidepsin	DCCAR0E	Docetaxel	Adenocarcinoma (Cell Line: NCIH23)	[5]
Docetaxel + Romidepsin	DCLJKIM	Docetaxel	Glioma (Cell Line: SF-539)	[5]
Docetaxel + Romidepsin	DCWCD63	Docetaxel	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Estramustine + Romidepsin	DCASYSX	Estramustine	Glioma (Cell Line: SF-539)	[5]
Estramustine + Romidepsin	DCELB2J	Estramustine	Papillary renal cell carcinoma (Cell Line: ACHN)	[5]
Estramustine + Romidepsin	DCIVBZX	Estramustine	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Estramustine + Romidepsin	DCPEDS3	Estramustine	Adenocarcinoma (Cell Line: NCIH23)	[4]
Etoposide + Romidepsin	DCZJSVE	Etoposide	Ewing sarcoma (Cell Line: TC-71)	[5]
Exherin + Romidepsin	DC0ZMZ1	Exherin	Ewing sarcoma (Cell Line: TC-71)	[5]
Fludarabine + Romidepsin	DCJLQ0B	Fludarabine	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[5]
Fludarabine + Romidepsin	DC96WF5	Fludarabine	Glioma (Cell Line: SF-539)	[5]
Fludarabine + Romidepsin	DCWI1D2	Fludarabine	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Fludarabine + Romidepsin	DCP7E2H	Fludarabine	Adenocarcinoma (Cell Line: NCIH23)	[4]
Fludarabine + Romidepsin	DCQP24C	Fludarabine	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Fludarabine + Romidepsin	DCSOU40	Fludarabine	Melanoma (Cell Line: MALME-3M)	[4]
Formononetin + Romidepsin	DC24IBD	Formononetin	Ewing sarcoma (Cell Line: TC-71)	[5]
GDC-0084 + Romidepsin	DC4UT2Y	GDC-0084	Ewing sarcoma (Cell Line: TC-71)	[5]
Gefitinib + Romidepsin	DC9YNPD	Gefitinib	Adenocarcinoma (Cell Line: A549)	[5]
Gefitinib + Romidepsin	DCK9YBX	Gefitinib	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Gefitinib + Romidepsin	DCWYOXS	Gefitinib	Astrocytoma (Cell Line: SNB-19)	[5]
Gefitinib + Romidepsin	DCE3Q0X	Gefitinib	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[5]
Gefitinib + Romidepsin	DC2RU83	Gefitinib	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Gefitinib + Romidepsin	DCD03J7	Gefitinib	Glioblastoma (Cell Line: SNB-75)	[5]
Gefitinib + Romidepsin	DC0AV23	Gefitinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Gefitinib + Romidepsin	DCMTIKZ	Gefitinib	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Gefitinib + Romidepsin	DC4SLYK	Gefitinib	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Gefitinib + Romidepsin	DC710JB	Gefitinib	Melanoma (Cell Line: MALME-3M)	[5]
Gefitinib + Romidepsin	DCMAZY7	Gefitinib	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Gefitinib + Romidepsin	DCV82W3	Gefitinib	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Gefitinib + Romidepsin	DCR7SCQ	Gefitinib	Papillary renal cell carcinoma (Cell Line: ACHN)	[5]
Gefitinib + Romidepsin	DC2OZMM	Gefitinib	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[5]
Gefitinib + Romidepsin	DC30M0P	Gefitinib	Renal cell carcinoma (Cell Line: UO-31)	[5]
Gefitinib + Romidepsin	DCTU0AP	Gefitinib	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Imatinib + Romidepsin	DCM2R3D	Imatinib	Renal cell carcinoma (Cell Line: UO-31)	[5]
Indazole derivative 5 + Romidepsin	DC933S2	Indazole derivative 5	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[5]
Indazole derivative 5 + Romidepsin	DCSFP7T	Indazole derivative 5	Chronic myelogenous leukemia (Cell Line: K-562)	[5]
Indazole derivative 5 + Romidepsin	DCBPA5F	Indazole derivative 5	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Ispinesib + Romidepsin	DCZ1HJO	Ispinesib	Ewing sarcoma (Cell Line: TC-71)	[5]
JNK-IN-8 + Romidepsin	DCFCRQJ	JNK-IN-8	Glioblastoma (Cell Line: SNB-75)	[5]
JNK-IN-8 + Romidepsin	DCDBKLG	JNK-IN-8	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
JNK-IN-8 + Romidepsin	DCZJW9L	JNK-IN-8	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
JNK-IN-8 + Romidepsin	DCAMQ9K	JNK-IN-8	Lung adenocarcinoma (Cell Line: EKVX)	[4]
JNK-IN-8 + Romidepsin	DCNZLHO	JNK-IN-8	Malignant melanoma (Cell Line: LOX IMVI)	[4]
JNK-IN-8 + Romidepsin	DCSD43C	JNK-IN-8	Melanoma (Cell Line: MALME-3M)	[4]
JNK-IN-8 + Romidepsin	DCXB5EW	JNK-IN-8	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
Lenalidomide + Romidepsin	DC1A03H	Lenalidomide	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Lenalidomide + Romidepsin	DCUDZCU	Lenalidomide	Adenocarcinoma (Cell Line: A549)	[4]
Lenalidomide + Romidepsin	DC0RN0G	Lenalidomide	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Lenalidomide + Romidepsin	DC8KPAK	Lenalidomide	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
Lenalidomide + Romidepsin	DCEPNMK	Lenalidomide	Malignant melanoma (Cell Line: LOX IMVI)	[4]
Lenalidomide + Romidepsin	DC1K15G	Lenalidomide	Prostate carcinoma (Cell Line: PC-3)	[4]
LIAROZOLE + Romidepsin	DCHWXQ8	LIAROZOLE	Glioma (Cell Line: SF-539)	[5]
LIAROZOLE + Romidepsin	DCFJFDS	LIAROZOLE	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
LIAROZOLE + Romidepsin	DC5EL4Y	LIAROZOLE	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
LY2874455 + Romidepsin	DCCKF4O	LY2874455	Ewing sarcoma (Cell Line: TC-71)	[5]
Mechlorethamine + Romidepsin	DC2ZX8K	Mechlorethamine	Adenocarcinoma (Cell Line: HCT-15)	[4]
Mechlorethamine + Romidepsin	DC0L1G0	Mechlorethamine	Malignant melanoma (Cell Line: LOX IMVI)	[4]
Methotrexate + Romidepsin	DCLYAPT	Methotrexate	Ewing sarcoma (Cell Line: TC-71)	[5]
Mitomycin + Romidepsin	DCA85TX	Mitomycin	Ewing sarcoma (Cell Line: TC-71)	[5]
MK-1775 + Romidepsin	DC1I7YU	MK-1775	Ewing sarcoma (Cell Line: TC-71)	[5]
OSI-027 + Romidepsin	DC4KHH3	OSI-027	Ewing sarcoma (Cell Line: TC-71)	[5]
PHA-739358 + Romidepsin	DCGTJMP	PHA-739358	Ewing sarcoma (Cell Line: TC-71)	[5]
Picoplatin + Romidepsin	DCD6SZ6	Picoplatin	Renal cell carcinoma (Cell Line: UO-31)	[5]
Raloxifene + Romidepsin	DCRTQSU	Raloxifene	Chronic myelogenous leukemia (Cell Line: K-562)	[5]
Raloxifene + Romidepsin	DCW41EI	Raloxifene	Renal cell carcinoma (Cell Line: UO-31)	[5]
Romidepsin + Buparlisib	DCIIDC4	Buparlisib	Ewing sarcoma (Cell Line: TC-71)	[5]
Romidepsin + LY335979	DCOVA6D	LY335979	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[5]
Romidepsin + Ixabepilone	DCQUK1N	Ixabepilone	Astrocytoma (Cell Line: U251)	[5]
Romidepsin + Ixabepilone	DCH3HCG	Ixabepilone	Clear cell renal cell carcinoma (Cell Line: TK-10)	[5]
Romidepsin + Dactinomycin	DCKJQ5W	Dactinomycin	Chronic myelogenous leukemia (Cell Line: K-562)	[5]
Romidepsin + Dactinomycin	DCKI06Q	Dactinomycin	Clear cell renal cell carcinoma (Cell Line: TK-10)	[5]
Romidepsin + Dactinomycin	DCUIJP6	Dactinomycin	Glioma (Cell Line: SF-539)	[5]
Romidepsin + Dactinomycin	DCTQXY2	Dactinomycin	Papillary renal cell carcinoma (Cell Line: ACHN)	[5]
Romidepsin + Dactinomycin	DCZGD6P	Dactinomycin	Renal cell carcinoma (Cell Line: SN12C)	[5]
Romidepsin + PMID28460551-Compound-2	DCB4TQG	PMID28460551-Compound-2	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[5]
Romidepsin + Methotrexate	DCTARHH	Methotrexate	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[5]
Romidepsin + Methotrexate	DCZBNDV	Methotrexate	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Romidepsin + Arsenic trioxide	DC30I5O	Arsenic trioxide	Renal cell carcinoma (Cell Line: UO-31)	[5]
Romidepsin + Plicamycin	DC9DG4T	Plicamycin	Glioma (Cell Line: SF-539)	[5]
Romidepsin + Plicamycin	DCI074Q	Plicamycin	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Romidepsin + Formononetin	DC5WKTT	Formononetin	Ewing sarcoma (Cell Line: TC-71)	[5]
Romidepsin + 10-hydroxycamptothecin	DCP3FGD	10-hydroxycamptothecin	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Romidepsin + 10-hydroxycamptothecin	DC54XWQ	10-hydroxycamptothecin	Astrocytoma (Cell Line: U251)	[5]
Romidepsin + 10-hydroxycamptothecin	DCOVAD6	10-hydroxycamptothecin	Astrocytoma (Cell Line: SNB-19)	[5]
Romidepsin + 10-hydroxycamptothecin	DCRD6IL	10-hydroxycamptothecin	Clear cell renal cell carcinoma (Cell Line: 786-0)	[5]
Romidepsin + 10-hydroxycamptothecin	DCOJBUO	10-hydroxycamptothecin	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[5]
Romidepsin + Topetecan	DCG54PP	Topetecan	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Romidepsin + Topetecan	DC00EBZ	Topetecan	Astrocytoma (Cell Line: U251)	[5]
Romidepsin + Topetecan	DCZVAEB	Topetecan	Astrocytoma (Cell Line: SNB-19)	[5]
Romidepsin + Topetecan	DCMU2D5	Topetecan	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[5]
Romidepsin + Topetecan	DCXNNBF	Topetecan	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Romidepsin + SCH 727965	DC8EFM9	SCH 727965	Ewing sarcoma (Cell Line: TC-71)	[5]
Romidepsin + Docetaxel	DCFPW0H	Docetaxel	Ewing sarcoma (Cell Line: TC-71)	[5]
Romidepsin + THAPSIGARGIN	DCAUEF3	THAPSIGARGIN	Ewing sarcoma (Cell Line: EW-8)	[5]
Romidepsin + THAPSIGARGIN	DC3I5NE	THAPSIGARGIN	Ewing sarcoma (Cell Line: TC-71)	[5]
Romidepsin + Marizomib	DCDMRDQ	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Romidepsin + Bendamustine hydrochloride	DC6SL1Z	Bendamustine hydrochloride	Renal cell carcinoma (Cell Line: UO-31)	[5]
Romidepsin + Mitomycin	DCXZJL2	Mitomycin	Clear cell renal cell carcinoma (Cell Line: 786-0)	[5]
Romidepsin + Mitomycin	DCGKD24	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Romidepsin + Mitomycin	DCFQFM2	Mitomycin	Ewing sarcoma (Cell Line: TC-71)	[5]
Romidepsin + Mitomycin	DCX9IQN	Mitomycin	Glioblastoma (Cell Line: SNB-75)	[5]
Romidepsin + OSI-906	DC28PBR	OSI-906	Ewing sarcoma (Cell Line: TC-71)	[5]
Romidepsin + Bleomycin	DC8THSJ	Bleomycin	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Romidepsin + Bleomycin	DCEUD0F	Bleomycin	Astrocytoma (Cell Line: U251)	[5]
Romidepsin + Bleomycin	DC4RFKU	Bleomycin	Glioma (Cell Line: SF-539)	[5]
Romidepsin + Bleomycin	DCWSEWS	Bleomycin	Glioma (Cell Line: SF-295)	[5]
Romidepsin + Bleomycin	DCWJ3I8	Bleomycin	Papillary renal cell carcinoma (Cell Line: ACHN)	[5]
Romidepsin + Bortezomib	DCB1DNY	Bortezomib	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Romidepsin + Valrubicin	DC4EPFT	Valrubicin	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[5]
Romidepsin + Valrubicin	DCUY1GF	Valrubicin	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Romidepsin + Valrubicin	DCYSS6E	Valrubicin	Clear cell renal cell carcinoma (Cell Line: A498)	[5]
Romidepsin + Valrubicin	DCVNXTC	Valrubicin	Clear cell renal cell carcinoma (Cell Line: 786-0)	[5]
Romidepsin + Valrubicin	DC20IEW	Valrubicin	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[5]
Romidepsin + Valrubicin	DC92CL0	Valrubicin	Papillary renal cell carcinoma (Cell Line: ACHN)	[5]
Romidepsin + Valrubicin	DCY8QRE	Valrubicin	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Romidepsin + Valrubicin	DC3M47H	Valrubicin	Renal cell carcinoma (Cell Line: SN12C)	[5]
Romidepsin + Cisplatin	DCLC0R6	Cisplatin	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Romidepsin + Cisplatin	DC38H9L	Cisplatin	Glioma (Cell Line: SF-268)	[5]
Romidepsin + Cisplatin	DC0L3QA	Cisplatin	Glioma (Cell Line: SF-539)	[5]
Romidepsin + Cisplatin	DCBUX1O	Cisplatin	Papillary renal cell carcinoma (Cell Line: ACHN)	[5]
Romidepsin + Azacitidine	DCNK7V3	Azacitidine	Glioma (Cell Line: SF-295)	[5]
Romidepsin + Azacitidine	DCNIJZQ	Azacitidine	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Romidepsin + Vinflunine	DCMEUL1	Vinflunine	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Romidepsin + Vinflunine	DCX9XVC	Vinflunine	Renal cell carcinoma (Cell Line: UO-31)	[5]
Romidepsin + Mercaptopurine	DC9HW13	Mercaptopurine	Glioma (Cell Line: SF-295)	[5]
Romidepsin + Mercaptopurine	DCQGRD4	Mercaptopurine	Papillary renal cell carcinoma (Cell Line: ACHN)	[5]
Romidepsin + Mercaptopurine	DC5NNKO	Mercaptopurine	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Romidepsin + CHS-828	DCIZHXI	CHS-828	Ewing sarcoma (Cell Line: TC-71)	[5]
Romidepsin + Mitotane	DC2E8HT	Mitotane	Ewing sarcoma (Cell Line: TC-71)	[5]
Romidepsin + Elacridar	DCHBJJF	Elacridar	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[5]
Romidepsin + Doxorubicin	DCYEV3M	Doxorubicin	Ewing sarcoma (Cell Line: TC-71)	[5]
Romidepsin + Aminolevulinic Acid Hydrochloride	DCM5Z4F	Aminolevulinic Acid Hydrochloride	Astrocytoma (Cell Line: U251)	[5]
Romidepsin + Aminolevulinic Acid Hydrochloride	DCH90BR	Aminolevulinic Acid Hydrochloride	Glioblastoma (Cell Line: SNB-75)	[5]
Romidepsin + Ixabepilone	DCG53HW	Ixabepilone	Carcinoma (Cell Line: RXF 393)	[6]
Romidepsin + Ixabepilone	DC1MGSD	Ixabepilone	Colon carcinoma (Cell Line: KM12)	[6]
Romidepsin + Ixabepilone	DCQZMME	Ixabepilone	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Romidepsin + Ixabepilone	DCIDIBH	Ixabepilone	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Romidepsin + Plicamycin	DC3UMUM	Plicamycin	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Romidepsin + Topetecan	DC2KOP0	Topetecan	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Romidepsin + Pralatrexate	DCH2142	Pralatrexate	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Romidepsin + Mitomycin	DCEZNO8	Mitomycin	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Romidepsin + Bleomycin	DC2IDPV	Bleomycin	Carcinoma (Cell Line: RXF 393)	[6]
Romidepsin + Valrubicin	DCZXCRU	Valrubicin	Carcinoma (Cell Line: MCF7)	[6]
Romidepsin + Valrubicin	DCMBDUU	Valrubicin	Colon carcinoma (Cell Line: KM12)	[6]
Romidepsin + Valrubicin	DCNADWX	Valrubicin	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Romidepsin + Cisplatin	DCJ5X3Z	Cisplatin	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Romidepsin + Chlorambucil	DC8L3IB	Chlorambucil	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Romidepsin + Chlorambucil	DCS1L2E	Chlorambucil	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Romidepsin + Chlorambucil	DCI8JXC	Chlorambucil	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Romidepsin + Azacitidine	DCECOP7	Azacitidine	Carcinoma (Cell Line: RXF 393)	[6]
Romidepsin + Aminolevulinic Acid Hydrochloride	DCMQ0TQ	Aminolevulinic Acid Hydrochloride	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Romidepsin + Fulvestrant	DCJB4H3	Fulvestrant	Adenocarcinoma (Cell Line: HT29)	[4]
Romidepsin + Ixabepilone	DCOJFQS	Ixabepilone	Adenocarcinoma (Cell Line: DU-145)	[4]
Romidepsin + Ixabepilone	DCT2AR8	Ixabepilone	Adenocarcinoma (Cell Line: OVCAR3)	[4]
Romidepsin + Ixabepilone	DC8TS4S	Ixabepilone	Adenocarcinoma (Cell Line: A549)	[4]
Romidepsin + Ixabepilone	DC9Z3ZF	Ixabepilone	Adenocarcinoma (Cell Line: HCT-15)	[4]
Romidepsin + Ixabepilone	DCBGZ1O	Ixabepilone	Adenocarcinoma (Cell Line: HCT116)	[4]
Romidepsin + Ixabepilone	DC5FZ27	Ixabepilone	Cutaneous melanoma (Cell Line: SK-MEL-5)	[4]
Romidepsin + Ixabepilone	DCLVQSJ	Ixabepilone	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[4]
Romidepsin + Ixabepilone	DCO56PM	Ixabepilone	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[4]
Romidepsin + Ixabepilone	DCC7GYI	Ixabepilone	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Romidepsin + Ixabepilone	DCOK3PZ	Ixabepilone	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
Romidepsin + Ixabepilone	DCU4CU5	Ixabepilone	Malignant melanoma (Cell Line: UACC62)	[4]
Romidepsin + Ixabepilone	DC9EU4V	Ixabepilone	Melanoma (Cell Line: UACC-257)	[4]
Romidepsin + Ixabepilone	DCHW0SQ	Ixabepilone	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[4]
Romidepsin + Lapatinib	DCYWS1E	Lapatinib	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Romidepsin + PMID28460551-Compound-2	DCIBAL0	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: DU-145)	[4]
Romidepsin + PMID28460551-Compound-2	DCON7H8	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: HT29)	[4]
Romidepsin + Isoniazid	DCAMSG7	Isoniazid	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[4]
Romidepsin + Arsenic trioxide	DC2CN7Z	Arsenic trioxide	Adenocarcinoma (Cell Line: OVCAR3)	[4]
Romidepsin + Arsenic trioxide	DCTG53M	Arsenic trioxide	Adenocarcinoma (Cell Line: HCT-15)	[4]
Romidepsin + Arsenic trioxide	DC9ZDL3	Arsenic trioxide	Cutaneous melanoma (Cell Line: SK-MEL-28)	[4]
Romidepsin + Plicamycin	DCR5HCA	Plicamycin	Adenocarcinoma (Cell Line: HCT-15)	[4]
Romidepsin + Plicamycin	DCFKHMP	Plicamycin	Cutaneous melanoma (Cell Line: SK-MEL-5)	[4]
Romidepsin + Plicamycin	DC37EXU	Plicamycin	Melanoma (Cell Line: MALME-3M)	[4]
Romidepsin + Plicamycin	DCZ8L94	Plicamycin	Melanoma (Cell Line: SK-MEL-2)	[4]
Romidepsin + Triapine	DCOG482	Triapine	Adenocarcinoma (Cell Line: OVCAR3)	[4]
Romidepsin + Triapine	DCN09A8	Triapine	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[4]
Romidepsin + Topetecan	DCYO5EA	Topetecan	Adenocarcinoma (Cell Line: A549)	[4]
Romidepsin + Topetecan	DCHPJMY	Topetecan	Cutaneous melanoma (Cell Line: SK-MEL-5)	[4]
Romidepsin + Topetecan	DCE96W5	Topetecan	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Romidepsin + Topetecan	DCP5X5A	Topetecan	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Romidepsin + Topetecan	DCRRSU7	Topetecan	Lung adenocarcinoma (Cell Line: HOP-62)	[4]
Romidepsin + Pralatrexate	DCUCPBC	Pralatrexate	Adenocarcinoma (Cell Line: DU-145)	[4]
Romidepsin + SCH 727965	DCC3BL0	SCH 727965	Adenocarcinoma (Cell Line: HT29)	[4]
Romidepsin + THAPSIGARGIN	DCXAIY5	THAPSIGARGIN	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
Romidepsin + THAPSIGARGIN	DCTZ6X3	THAPSIGARGIN	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
Romidepsin + Bendamustine hydrochloride	DC529HP	Bendamustine hydrochloride	Adenocarcinoma (Cell Line: HCT116)	[4]
Romidepsin + Mitomycin	DCD2NAR	Mitomycin	Adenocarcinoma (Cell Line: DU-145)	[4]
Romidepsin + Mitomycin	DCFC41L	Mitomycin	Adenocarcinoma (Cell Line: OVCAR3)	[4]
Romidepsin + Mitomycin	DC4C24I	Mitomycin	Adenocarcinoma (Cell Line: NCIH23)	[4]
Romidepsin + Mitomycin	DC446C3	Mitomycin	Adenocarcinoma (Cell Line: HT29)	[4]
Romidepsin + Mitomycin	DCYAYSK	Mitomycin	Adenocarcinoma (Cell Line: HCC-2998)	[4]
Romidepsin + Mitomycin	DCPR5MR	Mitomycin	Amelanotic melanoma (Cell Line: M14)	[4]
Romidepsin + Mitomycin	DC1JJUQ	Mitomycin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[4]
Romidepsin + Mitomycin	DC1IJG0	Mitomycin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[4]
Romidepsin + Mitomycin	DC2OJG5	Mitomycin	Lung adenocarcinoma (Cell Line: HOP-62)	[4]
Romidepsin + Mitomycin	DCGMVHT	Mitomycin	Malignant melanoma (Cell Line: LOX IMVI)	[4]
Romidepsin + Mitomycin	DCB78ED	Mitomycin	Malignant melanoma (Cell Line: UACC62)	[4]
Romidepsin + Bleomycin	DCS6XWQ	Bleomycin	Adenocarcinoma (Cell Line: NCIH23)	[4]
Romidepsin + Bleomycin	DCZ5TZD	Bleomycin	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[4]
Romidepsin + Bleomycin	DCVYN8O	Bleomycin	Lung adenocarcinoma (Cell Line: HOP-62)	[4]
Romidepsin + Bleomycin	DCCR2TV	Bleomycin	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
Romidepsin + Bleomycin	DCRPTR6	Bleomycin	Melanoma (Cell Line: SK-MEL-2)	[4]
Romidepsin + Bortezomib	DC6DUEJ	Bortezomib	Adenocarcinoma (Cell Line: DU-145)	[4]
Romidepsin + Bortezomib	DCA0RV8	Bortezomib	Cutaneous melanoma (Cell Line: SK-MEL-5)	[4]
Romidepsin + Bortezomib	DCZJ5CC	Bortezomib	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Romidepsin + Bortezomib	DCDQMQZ	Bortezomib	Malignant melanoma (Cell Line: UACC62)	[4]
Romidepsin + Bortezomib	DCBKFH3	Bortezomib	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
Romidepsin + Valrubicin	DCT8H5O	Valrubicin	Adenocarcinoma (Cell Line: NCIH23)	[4]
Romidepsin + Valrubicin	DC4JSF3	Valrubicin	Adenocarcinoma (Cell Line: HCC-2998)	[4]
Romidepsin + Valrubicin	DC4BGTA	Valrubicin	Amelanotic melanoma (Cell Line: MDA-MB-435)	[4]
Romidepsin + Valrubicin	DCPLV6P	Valrubicin	Amelanotic melanoma (Cell Line: M14)	[4]
Romidepsin + Valrubicin	DCH0KT7	Valrubicin	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[4]
Romidepsin + Valrubicin	DCXVAQL	Valrubicin	Lung adenocarcinoma (Cell Line: HOP-62)	[4]
Romidepsin + Valrubicin	DCNSBOI	Valrubicin	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[4]
Romidepsin + Valrubicin	DCD3T2V	Valrubicin	Non-small cell lung carcinoma (Cell Line: HOP-92)	[4]
Romidepsin + Valrubicin	DCUZ4PK	Valrubicin	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Romidepsin + Cisplatin	DC3B8RF	Cisplatin	Adenocarcinoma (Cell Line: A549)	[4]
Romidepsin + Cisplatin	DCEO3C7	Cisplatin	Adenocarcinoma (Cell Line: NCIH23)	[4]
Romidepsin + Cisplatin	DCJ5XCQ	Cisplatin	Cutaneous melanoma (Cell Line: SK-MEL-5)	[4]
Romidepsin + Cisplatin	DCMTM53	Cisplatin	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Romidepsin + Cisplatin	DCTFIT1	Cisplatin	Melanoma (Cell Line: MALME-3M)	[4]
Romidepsin + Chlorambucil	DCTEUYO	Chlorambucil	Cutaneous melanoma (Cell Line: SK-MEL-5)	[4]
Romidepsin + Chlorambucil	DC7E1JH	Chlorambucil	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[4]
Romidepsin + Chlorambucil	DCVGO4J	Chlorambucil	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Romidepsin + Azacitidine	DC9DK6H	Azacitidine	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Romidepsin + Azacitidine	DCTG5LS	Azacitidine	Malignant melanoma (Cell Line: UACC62)	[4]
Romidepsin + Mercaptopurine	DCQUP06	Mercaptopurine	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Romidepsin + Mercaptopurine	DCOB3UN	Mercaptopurine	Malignant melanoma (Cell Line: UACC62)	[4]
Romidepsin + Mercaptopurine	DC4PV12	Mercaptopurine	Non-small cell lung carcinoma (Cell Line: HOP-92)	[4]
Romidepsin + PMID28870136-Compound-43	DC4MSSC	PMID28870136-Compound-43	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Romidepsin + FORMESTANE	DC7Y3CJ	FORMESTANE	Adenocarcinoma (Cell Line: HCT-15)	[4]
Romidepsin + Aminolevulinic Acid Hydrochloride	DCNOZHK	Aminolevulinic Acid Hydrochloride	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Romidepsin + Aminolevulinic Acid Hydrochloride	DCN6VAJ	Aminolevulinic Acid Hydrochloride	Lung adenocarcinoma (Cell Line: HOP-62)	[4]
Romidepsin + Aminolevulinic Acid Hydrochloride	DCMRRV9	Aminolevulinic Acid Hydrochloride	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
Romidepsin + Aminolevulinic Acid Hydrochloride	DCB09N8	Aminolevulinic Acid Hydrochloride	Malignant melanoma (Cell Line: LOX IMVI)	[4]
Romidepsin + Busulfan	DCCN4KA	Busulfan	Adenocarcinoma (Cell Line: HCT-15)	[4]
Ruxolitinib + Romidepsin	DCNYLM3	Ruxolitinib	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[5]
Ruxolitinib + Romidepsin	DC24GQM	Ruxolitinib	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Ruxolitinib + Romidepsin	DCPBQ5W	Ruxolitinib	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
Sirolimus + Romidepsin	DC7WGIC	Sirolimus	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Sirolimus + Romidepsin	DCAXN2S	Sirolimus	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Steroid derivative 1 + Romidepsin	DC9O74K	Steroid derivative 1	Ewing sarcoma (Cell Line: TC-71)	[5]
THAPSIGARGIN + Romidepsin	DCS8JQ5	THAPSIGARGIN	Ewing sarcoma (Cell Line: TC-71)	[5]
Thioguanine + Romidepsin	DCGXTKB	Thioguanine	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Thioguanine + Romidepsin	DC3BBPT	Thioguanine	Glioblastoma (Cell Line: SNB-75)	[5]
Thioguanine + Romidepsin	DC76X7Q	Thioguanine	Glioma (Cell Line: SF-295)	[5]
Thioguanine + Romidepsin	DCURW51	Thioguanine	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Thioguanine + Romidepsin	DCB92I8	Thioguanine	Amelanotic melanoma (Cell Line: MDA-MB-435)	[4]
Thioguanine + Romidepsin	DCK5N87	Thioguanine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[4]
Thioguanine + Romidepsin	DCPBU6U	Thioguanine	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Thioguanine + Romidepsin	DCXHW4P	Thioguanine	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Thioguanine + Romidepsin	DCM3QT7	Thioguanine	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
Thioguanine + Romidepsin	DCT2N7S	Thioguanine	Malignant melanoma (Cell Line: UACC62)	[4]
Thioguanine + Romidepsin	DC985B4	Thioguanine	Melanoma (Cell Line: MALME-3M)	[4]
Thioguanine + Romidepsin	DC8EZ96	Thioguanine	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
Topotecan + Romidepsin	DCG2PT3	Topotecan	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Topotecan + Romidepsin	DC1Q4RP	Topotecan	Adenocarcinoma (Cell Line: A549)	[4]
Topotecan + Romidepsin	DCGX23B	Topotecan	Adenocarcinoma (Cell Line: SW-620)	[4]
Topotecan + Romidepsin	DCTQERC	Topotecan	Glioma (Cell Line: SF-268)	[4]
Topotecan + Romidepsin	DC2HXKH	Topotecan	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Topotecan + Romidepsin	DCYMPP2	Topotecan	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Topotecan + Romidepsin	DCPTY55	Topotecan	Malignant melanoma (Cell Line: LOX IMVI)	[4]
Topotecan + Romidepsin	DC6K40J	Topotecan	Melanoma (Cell Line: UACC-257)	[4]
Topotecan + Romidepsin	DCIXHNP	Topotecan	Melanoma (Cell Line: MALME-3M)	[4]
Topotecan + Romidepsin	DCNI3UD	Topotecan	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[4]
Topotecan + Romidepsin	DC7B60V	Topotecan	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
Topotecan + Romidepsin	DCBIIBK	Topotecan	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Topotecan + Romidepsin	DCAJ5ZS	Topotecan	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
Topotecan + Romidepsin	DC82IOA	Topotecan	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[4]
Topotecan + Romidepsin	DCZ1QIP	Topotecan	Prostate carcinoma (Cell Line: PC-3)	[4]
Trifluridine + Romidepsin	DC1M1LW	Trifluridine	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Trifluridine + Romidepsin	DC8C7Z3	Trifluridine	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Trifluridine + Romidepsin	DC4T9TN	Trifluridine	Malignant melanoma (Cell Line: LOX IMVI)	[4]
Trifluridine + Romidepsin	DC04BQG	Trifluridine	Melanoma (Cell Line: UACC-257)	[4]
Trifluridine + Romidepsin	DCT6LU1	Trifluridine	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[4]
Trifluridine + Romidepsin	DCT65RS	Trifluridine	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[4]
Uracil mustard + Romidepsin	DCH0I78	Uracil mustard	Chronic myelogenous leukemia (Cell Line: K-562)	[5]
Uracil mustard + Romidepsin	DCYC81L	Uracil mustard	Clear cell renal cell carcinoma (Cell Line: TK-10)	[5]
Uracil mustard + Romidepsin	DCNJZ9P	Uracil mustard	Glioblastoma (Cell Line: SNB-75)	[5]
Uracil mustard + Romidepsin	DCB2HBL	Uracil mustard	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Uracil mustard + Romidepsin	DCZYDGE	Uracil mustard	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Uracil mustard + Romidepsin	DCF26R2	Uracil mustard	Adenocarcinoma (Cell Line: DU-145)	[4]
Uracil mustard + Romidepsin	DCRWHDH	Uracil mustard	Adenocarcinoma (Cell Line: A549)	[4]
Uracil mustard + Romidepsin	DC0NKSI	Uracil mustard	Adenocarcinoma (Cell Line: HT29)	[4]
Uracil mustard + Romidepsin	DCQENWB	Uracil mustard	Adenocarcinoma (Cell Line: SW-620)	[4]
Uracil mustard + Romidepsin	DCN35B3	Uracil mustard	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Uracil mustard + Romidepsin	DCUEQ7P	Uracil mustard	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Uracil mustard + Romidepsin	DCSTN2D	Uracil mustard	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
Uracil mustard + Romidepsin	DCZXJT6	Uracil mustard	Melanoma (Cell Line: MALME-3M)	[4]
Uracil mustard + Romidepsin	DC1DYYS	Uracil mustard	Melanoma (Cell Line: UACC-257)	[4]
Uracil mustard + Romidepsin	DCO84QV	Uracil mustard	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
Uracil mustard + Romidepsin	DCSYUEO	Uracil mustard	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[4]
Valrubicin + Romidepsin	DCJUTXH	Valrubicin	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[5]
Valrubicin + Romidepsin	DCOTCEX	Valrubicin	Astrocytoma (Cell Line: SNB-19)	[5]
Valrubicin + Romidepsin	DCRI0Y6	Valrubicin	Glioma (Cell Line: SF-539)	[5]
Valrubicin + Romidepsin	DCEDMIP	Valrubicin	Renal cell carcinoma (Cell Line: UO-31)	[5]
Valrubicin + Romidepsin	DCDE07Y	Valrubicin	Renal cell carcinoma (Cell Line: SN12C)	[5]
Valrubicin + Romidepsin	DCEU9ID	Valrubicin	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Valrubicin + Romidepsin	DC6L0N4	Valrubicin	Carcinoma (Cell Line: MCF7)	[6]
Valrubicin + Romidepsin	DCNDOX1	Valrubicin	Adenocarcinoma (Cell Line: A549)	[4]
Valrubicin + Romidepsin	DC4CR6E	Valrubicin	Adenocarcinoma (Cell Line: NCIH23)	[4]
Valrubicin + Romidepsin	DCS9LBR	Valrubicin	Adenocarcinoma (Cell Line: HCT-15)	[4]
Valrubicin + Romidepsin	DCCUY18	Valrubicin	Cutaneous melanoma (Cell Line: SK-MEL-28)	[4]
Valrubicin + Romidepsin	DCVYI6K	Valrubicin	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[4]
Vandetanib + Romidepsin	DC5FXKO	Vandetanib	Chronic myelogenous leukemia (Cell Line: K-562)	[4]
Vandetanib + Romidepsin	DC0PRXQ	Vandetanib	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Vincristine + Romidepsin	DCD4MG3	Vincristine	Adenocarcinoma (Cell Line: NCIH23)	[5]
Vinflunine + Romidepsin	DCKGDN4	Vinflunine	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Vinflunine + Romidepsin	DCMYDPA	Vinflunine	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Vismodegib + Romidepsin	DC56ENP	Vismodegib	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
Vismodegib + Romidepsin	DC1K5A1	Vismodegib	Lung adenocarcinoma (Cell Line: EKVX)	[4]
Ym155 + Romidepsin	DCJW4EK	Ym155	Ewing sarcoma (Cell Line: TC-71)	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 432 DrugCom(s)

22 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Bay 80-6946 + Romidepsin	DCAXH8V	Bay 80-6946	Lymphoma, T-Cell	[7]
Bortezomib + Romidepsin	DC0H84Q	Bortezomib	Leukemia	[8]
Bortezomib + Romidepsin	DC31YGY	Bortezomib	Multiple Myeloma	[9]
Carfilzomib + Romidepsin	DC4FRYE	Carfilzomib	Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma	[10]
Carfilzomib + Romidepsin	DCPYXK2	Carfilzomib	Peripheral T Cell Lymphoma	[11]
Decitabine + Romidepsin	DCP6OCA	Decitabine	Chronic Myeloproliferative Disorders	[12]
Decitabine + Romidepsin	DCZ8FN7	Decitabine	HIV-1-infection, Subtype b	[13]
Dexamethasone + Romidepsin	DCTGZ6D	Dexamethasone	Multiple Myeloma	[14]
Duvelisib + Romidepsin	DCSXV9B	Duvelisib	Lymphoma	[15]
Gemcitabine + Romidepsin	DCJRJEX	Gemcitabine	Pancreatic Cancer	[16]
Ketoconazole + Romidepsin	DC6KLH4	Ketoconazole	Hematologic Malignancy	[17]
Lenalidomide + Romidepsin	DCVYV4M	Lenalidomide	Multiple Myeloma	[18]
Pralatrexate + Romidepsin	DCNYOYY	Pralatrexate	Lymphoid Malignancies	[19]
Rifampicin + Romidepsin	DCV7QYD	Rifampicin	Hematologic Malignancy	[20]
Romidepsin + Fludarabine	DC2WH9H	Fludarabine	Recurrent Grade 1 Follicular Lymphoma	[21]
Romidepsin + RP6530	DC4NK5Q	RP6530	T Cell Lymphoma	[22]
Romidepsin + Azacitidine	DC7JHI1	Azacitidine	Lymphoid Malignancies	[23]
Artesunate + Romidepsin	DCAB9X9	Artesunate	Hiv	[24]
Lenalidomide + Romidepsin	DC9Q0YM	Lenalidomide	Adult Nasal Type Extranodal NK/T-cell Lymphoma	[25]
Venetoclax + Romidepsin	DCE49GC	Venetoclax	Anaplastic Large Cell Lymphoma	[26]
Gemcitabine + Romidepsin	DCPJTMZ	Gemcitabine	Relapsed Angioimmunoblastic T-Cell Lymphoma	[27]
Pralatrexate + Romidepsin	DCJXGGX	Pralatrexate	Lymphoma, T-Cell, Peripheral	[28]
------------------------------------------------------------------------------------


⏷ Show the Full List of 22 DrugCom(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7006).
2	Romidepsin FDA Label
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
7	ClinicalTrials.gov (NCT04233697) Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
8	ClinicalTrials.gov (NCT00963274) Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
9	ClinicalTrials.gov (NCT00765102) Trial of Romidepsin and Bortezomib for Multiple Myeloma
10	ClinicalTrials.gov (NCT01738594) Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
11	ClinicalTrials.gov (NCT03141203) Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
12	ClinicalTrials.gov (NCT00114257) Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
13	ClinicalTrials.gov (NCT05230368) Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load
14	ClinicalTrials.gov (NCT01979276) Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
15	ClinicalTrials.gov (NCT02783625) Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
16	ClinicalTrials.gov (NCT00379639) A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors
17	ClinicalTrials.gov (NCT01324310) Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
18	ClinicalTrials.gov (NCT01755975) Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
19	ClinicalTrials.gov (NCT01947140) Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
20	ClinicalTrials.gov (NCT01324323) Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
21	ClinicalTrials.gov (NCT00079443) FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
22	ClinicalTrials.gov (NCT03770000) Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
23	ClinicalTrials.gov (NCT01998035) Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
24	ClinicalTrials.gov (NCT03041012) Early Administration of Romidepsin and 3BNC117 in Treatment-nave HIV Patients Starting ART
25	ClinicalTrials.gov (NCT02232516) Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
26	ClinicalTrials.gov (NCT03534180) Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
27	ClinicalTrials.gov (NCT03593018) Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL
28	ClinicalTrials.gov (NCT03355768) Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL